Abstract: A method of implementing a destination is disclosed. A definition of the destination is received via an API. The definition includes a definition of an action. The definition of the action represents an interaction with an API associated with the destination. The definition of the action includes one or more definitions of one or more input fields associated with the action. The action is surfaced in a user interface. The surfacing includes presenting a graphical representation of the one or more input fields based on the one or more definitions of the one or more input fields. One or more inputs is received via the graphical representation of the one or more input fields. Event data is routed from one or more data sources to the destination. The routing includes mapping the event data to the destination based on the one or more inputs.

Abstract: A method of sending information from one or more sources to one or more destinations is disclosed. A definition of a destination action is received. The definition of the destination action includes a trigger sub-component and a mapping sub-component. Based on an activation of the trigger, the action is performed. The performing of the action includes sending the information to the one or more destinations. The sending of the information includes sending data from one or more fields at the one or more sources to one or more fields at the destination. The one or more fields from the one or more sources are mapped to the one or more fields at the destination.

Abstract: It has now been discovered that arsenic induces herpes viruses latent in infected cells to reactivate to the lytic stage. Herpes viruses in the lytic stage activate anti-herpes virus anti viral agents. Co-administration of arsenic compounds and anti-herpes viral agents to a population of cells infected with a herpes virus results in the death of the cells and inhibits proliferation of the virus. The invention is therefore useful for reducing a subject's population of cells infected with herpes viruses, particularly Epstein-Barr virus.

Abstract: 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof can be used in the treatment of pulmonary fibrosis.

Abstract: The present invention pertains to the use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of pulmonary hypertension.